As lipid-based nanoparticles advance beyond hepatic applications, developers must evaluate whether passive or active targeting strategies best balance delivery efficiency with manufacturability and regulatory feasibility. This interactive workshop will explore the scientific, technical, and regulatory trade-offs shaping the future of extrahepatic LNP delivery.

This workshop will gather experts to discuss:

• Comparing active and passive targeting strategies, from antibody-based approaches to passive tissue tropism driven by lipid composition and emerging 5th-component designs
• Assessing efficacy and manufacturability by delving into potency, endosomal escape, scalability, CMC complexity, and ligand stability during manufacturing for active versus passive LNPs
• Delving into toxicology and pharmacology of targeting moieties, potential biological interference, and practical considerations for regulatory approval of targeted LNP system